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The activities of short synthetic, nonhemolytic peptides derived from the C-terminal region of myotoxin II,
a catalytically inactive phospholipase A2 homologue present in the venom of the snake Bothrops asper, have
been shown to reproduce the bactericidal activity of the parent protein. They combine cationic and hydropho-
bic-aromatic amino acids, thus functionally resembling the antimicrobial peptides of innate defenses. This
study evaluated the antimicrobial and antiendotoxic properties of a 13-mer derivative peptide of the C-terminal
sequence from positions 115 to 129 of myotoxin II, named pEM-2. This peptide (KKWRWWLKALAKK) showed
bactericidal activity against both gram-positive and gram-negative bacteria. In comparison to previously
described peptide variants derived from myotoxin II, the toxicity of pEM-2 toward eukaryotic cells in culture
was significantly reduced, being similar to that of lactoferricin B but lower than that of polymyxin B. The all-D
enantiomer of pEM-2 [pEM-2 (D)] retained the same bactericidal potency of its L-enantiomeric counterpart,
but it showed an enhanced ability to counteract the lethal activity of an intraperitoneal lipopolysaccharide
challenge in mice, which correlated with a significant reduction of the serum tumor necrosis factor alpha levels
triggered by this endotoxin. Lethality induced by intraperitoneal infection of mice with Escherichia coli or Salmo-
nella enterica serovar Typhimurium was reduced by the administration of pEM-2 (D). These results demon-
strate that phospholipase A2-derived peptides may have the potential to counteract microbial infections and
encourage further evaluations of their actions in vivo.
Microbicidal cationic peptides have emerged as promising
therapeutic alternatives to cope with the increasing rates of
antibiotic resistance encountered worldwide (15). In higher ani-
mals, a number of cationic peptides are localized at sites highly
exposed to microorganisms, such as the skin; intestine; lungs;
and body secretions, such as tears, sweat, and saliva (16, 27).
They are now considered key components of the innate im-
mune defenses, with physiologically relevant activities against
both gram-negative and gram-positive bacteria, protozoa, and
fungi (39). More than 500 cationic peptides have been isolated
from mammals, amphibians, arthropods, plants, bacteria, and
even viruses (15).
On the other hand, several types of mammalian secreted
phospholipases A2 (PLA2s; EC 3.1.1.4) have been reported to
exert potent bactericidal actions that are dependent on their
enzymatic activities (5, 18, 19, 20, 30, 37). Notably, a group of
PLA2 homologues present in snake venoms, known as Lys49
PLA2s (13, 24), have also been shown to be bactericidal, even
though they lack enzymatic activity (29, 34). In the case of
myotoxin II, a Lys49 PLA2 isolated from the venom of the
snake Bothrops asper, this bactericidal effect was reproduced by
a synthetic 13-mer peptide corresponding to the sequence from
positions 115 to 129 located at its C-terminal loop (p115-129).
Thus, an enzymatically independent bactericidal effect of a
PLA2 protein was demonstrated for the first time and was
mapped to a specific membrane-damaging protein site (21, 29).
Although p115-129, which is derived from a snake venom
PLA2, does not have significant sequence homology with any
known cationic peptides of the innate defenses, it shows func-
tional similarities with them. Previous studies showed that this
peptide interacts with lipopolysaccharide (LPS) and lipid A
from different gram-negative bacteria or with lipoteichoic acid
from Staphylococcus aureus and relies on a membrane-perme-
abilizing mechanism to exert its bactericidal effects (29). LPS is
a complex molecule composed of a fatty acid (lipid A), an O-
polysaccharide chain, and a core sugar, inserted into the outer
membrane of gram-negative bacteria. It plays a major role in
the pathophysiology of septic shock and promotes a massive
activation of macrophages, endothelial cells, and fibroblasts,
which release diverse proinflammatory mediators, such as tu-
mor necrosis factor alpha (TNF-), interleukin-1 (IL-1),
IL-6, and nitric oxide (1, 14). Severely affected patients present
with fever, shock, disseminated intravascular coagulation, mul-
tiple-organ failure, and death (1, 11).
Variants of the original p115-129 sequence have recently
been tested in vitro with the aim of optimizing its bactericidal
activity while minimizing its toxicity toward eukaryotic cells.
Such studies identified a peptide variant, named pEM-2, as an
interesting candidate for further evaluation of its antimicrobial
potential (32). Therefore, in the present investigation, the bac-
tericidal activities and antiendotoxic properties of synthetic
pEM-2 in both its L- and D-enantiomeric forms were charac-
terized in vitro and in vivo.
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MATERIALS AND METHODS
Peptide synthesis. Peptides were derived from the sequence from positions
115 to 129 (KKYRYYLKPLCKK) of B. asper myotoxin II (29), with some
modifications. They were synthesized by N-(9 fluorenyl)-methoxycarbonyl chem-
istry, as described previously (8). Peptide p115-W3 (KKWRWWLKPLCKK)
corresponds to a peptide with a triple tyrosine-to-tryptophan substitution (23),
whereas in pEM-2 (KKWRWWLKALAKK) the proline and cysteine residues of
p115-W3 were each replaced by an alanine residue. The latter peptide was
synthesized in its L- and D-enantiomeric forms. All peptides were purified by
reverse-phase high-performance liquid chromatography and were obtained with
95% final purity. Their observed molecular masses corresponded to the ex-
pected theoretical values. Peptides were stored dry at 20°C and were dissolved
in sterile pyrogen-free saline solution (0.15 M NaCl) immediately before use.
Bacteria, LPS, and antimicrobials. Bacteria were maintained at 70°C in
Trypticase soy broth (TSB) containing 10% (vol/vol) glycerol. Frozen stocks were
thawed and cultured for 4 h (enterobacteria) or overnight (Brucella spp.) in TSB.
Purified Escherichia coli O111:H4 LPS was kindly provided by A. Weintraub
(Karolinska Institute, Stockholm, Sweden). Lyophilized LPS was diluted in en-
dotoxin-free saline and was dispersed by sonication for 30 s, immediately before
use. Polymyxin B sulfate was obtained from Sigma (St. Louis, Mo.), whereas
lactoferricin B was kindly provided by W. Bellamy (Morinaga Dairy Co., Hi-
gashihara, Japan).
Bactericidal assay. Bactericidal activities were assayed as described previously
(29). Briefly, log-phase bacteria were obtained from TSB cultures, and their
concentration was adjusted to 4  106 CFU/ml in 0.01 M phosphate buffer (pH
7.4) containing 1% peptone (buffer A) by reading the absorbance at 540 nm
(enterobacteria) or 420 nm (Brucella spp.). One hundred microliters of these
suspensions, which contained 4  105 CFU, was incubated with 10 l of various
concentrations of peptides or buffer A alone for 20 min. Then, the remaining
viable bacteria were counted by plating appropriate dilutions on Trypticase soy
or blood agar after 24 h of growth at 37°C. The minimal microbicidal concen-
tration (MMC) was defined as the lowest peptide concentration that resulted in
the complete absence of bacterial growth after the bacteria were plated on agar.
Cytolytic activity. The cytolytic effects of the peptides were determined with
the murine skeletal muscle myoblast cell line C2C12 (ATCC CRL-1772), as
described previously (22). C2C12 is the most sensitive target for Lys49 PLA2-
derived peptides and their parent proteins. In brief, cells were grown in 96-well
plates in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
penicillin-streptomycin solution (100 U of penicillin per ml, 100 g of strepto-
mycin per ml) and 15% fetal calf serum (FCS) in an atmosphere with 7% CO2
at 37°C. Immediately before the experiment, the growth medium was removed
and then various amounts of the peptides (12.5, 25, 50, and 100 g) were added
to the assay medium (DMEM with 1% FCS). After 3 h at 37°C, the supernatants
were collected and the activity of lactate dehydrogenase released from the
damaged cells was determined (Sigma kit 500). Controls for 0 and 100% toxicity
values consisted of assay medium and 0.1% Triton X-100 in assay medium,
respectively.
LAL assay. In vitro neutralization of LPS activity was assessed by the Limulus
amoebocyte lysate (LAL) chromogenic assay (BioWhittaker, Walkersville, Md.).
In brief, E. coli LPS was solubilized at a concentration of 5 endotoxin units/ml by
sonication in endotoxin-free water. Peptides were prepared at concentrations of
12.5, 25, 50, 100, and 200 g/ml. Fifty microliters of endotoxin was mixed with
50 l of the different peptide solutions in a 96-well plate, and the plate was in-
cubated at 37°C for 20 min. Then, 100 l of LAL reagent was added to each well,
and the plate was incubated for 10 min at 37°C. Finally, 100 l of substrate (the
colorless peptide acetyl-Ile-Glu-Ala-Arg-para-nitroaniline) was added, and the
plate was incubated at 37°C for 6 min. The reactions were stopped with 100 l
of 25% (vol/vol) acetic acid. The final absorbances at 405 nm were determined
on a microplate reader (Labsystems). Assays were performed in triplicate wells,
and the results were expressed as the percent inhibition compared with the
control endotoxin activity values.
LPS stimulation of RAW 264.7 cells. The murine macrophage cell line RAW
264.7 (ATCC TIB-71) was grown in DMEM, as described above. Twenty-four
hours before stimulation, the cells were washed with DMEM containing 15%
FCS and detached by gentle scraping. Then, 5  105 cells were seeded into
24-well plates and were allowed to adhere overnight. Immediately before stim-
ulation, the growth medium was removed, and the cells were washed three times
in serum-free DMEM and then incubated with various concentrations of pep-
tides (0,12.5, 25, 50, 100, and 200 g/ml) in 500 l of DMEM. After 10 min, LPS
(100 ng/ml) was added to the wells, and the mixture was incubated for 3 h at
37°C. The supernatants were collected and stored at 70°C until they were
assayed. TNF- levels in serum or the cell culture supernatants were determined
by an enzyme-linked immunosorbent assay (R&D Systems, Milwaukee, Wis.).
Samples were diluted 1:6 and assayed in duplicate wells in at least two indepen-
dent experiments. All experiments were performed with a minimum of 90%
viability, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) reduction assay (28).
Endotoxic shock model. In order to corroborate the neutralization of LPS by
pEM-2 observed in vitro by the LAL assay, experiments were also carried out
with CD-1 mice. All in vivo assays were approved by the Committee for Animal
Care and Use, University of Costa Rica. Endotoxic shock was induced by intra-
peritoneal (i.p.) injection of E. coli O111:H4 LPS. Mice were presensitized with
an i.p. injection of 15 mg of D-galactosamine 1 h before the LPS challenge (10).
Three groups of mice (body weight, 16 to 18 g) received an i.p. injection con-
taining (i) 10 g of LPS alone, (ii) 50 g of pEM-2 alone, or (iii) a mixture of LPS
(10 g) and pEM-2 (50 g) preincubated for 20 min at 37°C. One hour after
injection, a blood sample was collected by retroorbital bleeding and serum was
obtained in order to quantify TNF- levels, as described above. Lethality was
recorded after 24, 48, and 72 h.
Bacterial peritonitis model. Three groups of CD-1 mice (body weight, 21 to
26 g) received an i.p. injection of (i) 5 108 E. coli or 2 106 Salmonella enterica
serovar Typhimurium CFU (obtained from log-phase TSB cultures) in 0.25 ml of
saline, (ii) the bacteria followed immediately by 100 g of the all-D enantiomer
of pEM-2 [pEM-2 (D)] in 0.25 ml of saline, or (iii) 100 g of pEM-2 (D) alone.
Lethality was recorded daily over an observation period of 5 days.
Statistical analyses. All endotoxin and TNF- experiments were performed in
triplicate. At least two independent assays were performed for all data collection.
Values are expressed as means standard deviations (SDs) and were statistically
compared by Fisher’s exact test, an unpaired Student’s t test, or analysis of
variance, as appropriate, by using InStat (version 2.04) GraphPad software.
RESULTS
Microbicidal activity of p115-129 variants. As assessed by
the broth microdilution method, a triple Trp3Tyr substitution
in p115-129 enhanced its microbicidal action against both
gram-negative (S. enterica serovar Typhimurium) and gram-
positive (S. aureus) bacteria or some resistant bacteria, such as
Brucella abortus (Fig. 1). The greatest enhancement in the
activity of p115-W3 was observed against S. enterica serovar
Typhimurium, suggesting a stronger interaction with compo-
FIG. 1. Bactericidal activities of synthetic myotoxin II peptide
p115-129 (F) and modified peptide p115-W3 (■) against S. aureus
ATCC 23923 (A), S. enterica serovar Typhimurium ATCC 14028 (B),
B. abortus 2308 (C), and B. abortus 45/20 (D). Each point represents
the mean  SD of triplicate viable counts, as described in Materials
and Methods.
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nents of the gram-negative bacterial membrane. Two addi-
tional changes were introduced in the sequence of p115-W3.
Its cysteine and proline were replaced by two alanine residues,
respectively, in order to avoid oxidative dimerization (Cys) and
to facilitate synthesis (Pro). This peptide, named pEM-2, dis-
played bactericidal activity against S. aureus and S. enterica
serovar Typhimurium (Table 1) similar to that of p115-W3. In
addition, pEM-2 showed strong action against other gram-
negative bacteria, such as Pseudomonas aeruginosa, Shigella
sonnei, and Vibrio cholerae, with MMCs of 1 g/ml, and a lower
level of activity against Klebsiella pneumoniae, with an MMC of
20 g/ml (Table 1). In comparison, pEM-2 (D) was evaluated
for its bactericidal activity. As shown in Fig. 2, pEM-2 (D)
displayed microbicidal activity similar to that of its L-enantio-
meric counterpart against S. enterica serovar Typhimurium and
S. aureus. Both enantiomers of pEM-2 showed higher levels of
activity than lactoferricin B (Fig. 2).
Comparative cytolytic activities of p115-W3 and pEM-2. It
was previously reported that even though p115-W3 is nonhe-
molytic, it displays a marked toxic effect toward eukaryotic
cells in comparison to that of the original p115-129 of myotoxin
II (23). As shown in Fig. 3, 150 g of p115-W3 per ml caused
100% lysis of murine muscle cells, an effect more potent than
that of polymyxin B. In contrast, pEM-2 exerted significantly
weaker activity against these cells, reaching only half-maximal
toxicity at the highest dose tested (600 g/ml). The minimal
concentration of pEM-2 required to induce complete lysis of
the cultures in vitro was estimated to be 	2.7 mg/ml (data not
shown). The toxic activity of pEM-2 in this assay was similar to
that of lactoferricin B (Fig. 3), a bactericidal peptide derived
from mammalian lactoferrin.
In vitro endotoxin-neutralizing activities of pEM-2 enanti-
omers. In order to evaluate the endotoxin-neutralizing ability
of pEM-2, both of its enantiomers were tested in the LAL
assay. pEM-2 (L) showed significant LPS-neutralizing activity,
similar to that of polymyxin B, whereas pEM-2 (D) also inhib-
ited endotoxin, although to a lower degree (Fig. 4). Control
peptides alone did not induce a response in the LAL assay.
Effects of pEM-2 enantiomers on TNF- secretion in vitro.
In order to assess the inhibition of LPS-induced TNF- release
by pEM-2, RAW 264.7 macrophages were challenged with 100
ng of LPS per ml, either alone or in combination with different
concentrations of peptides. Control experiments indicated that
at the concentrations used the peptides alone were not toxic
TABLE 1. Microbicidal spectrum of pEM-2 (L)
against various bacteria
Bacterium MMC(g/ml)a
Pseudomonas aeruginosa ATCC 27853 ......................................... 1
Vibrio cholerae Ogawa IMS 124..................................................... 1
Shigella sonnei ATCC 25931 .......................................................... 1
Escherichia coli ATCC 25922......................................................... 5
Salmonella enterica serovar Typhimurium D984 ......................... 5
Enterococcus faecalis ATCC 29212................................................ 5
Staphylococcus aureus ATCC 23923.............................................. 5
Klebsiella pneumoniae ATCC 13883.............................................. 20
Brucella abortus 45.20......................................................................250
a Assays were performed in triplicate. MMCs refer to the minimum peptide
concentrations that completely killed bacteria in liquid medium, as evidenced by
the lack of subsequent growth after plating of appropriate dilutions in agar, as
described in Materials and Methods.
FIG. 2. Bactericidal activity of the L enantiomer (F) and the D
enantiomer (■) of synthetic peptide pEM-2 against S. enterica serovar
Typhimurium ATCC 14028 (A) and S. aureus ATCC 23923 (B). Poly-
myxin B (Œ) and lactoferricin B (E) were included for comparison.
Each point represents the mean  SD of triplicate viable counts.
FIG. 3. Cytotoxic activities of p115-W3 (F) and pEM-2 (Œ) on
C2C12 myoblasts. Polymyxin B (■) and lactoferricin B (}) were in-
cluded for comparison. Each point represents the mean  SD of
triplicate cultures.
FIG. 4. Inhibition of the endotoxin activity of LPS in vitro (by the
chromogenic LAL assay) by the L enanatiomer (F) and the D enan-
tiomer (■) of pEM-2. Polymyxin B (Œ) was included as a reference.
Each point represents the mean  SD of triplicate assays.
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for these cells, since there was no TNF- release, and the
viability (as judged by MTT-reducing activity) was nearly 100%
in all wells. Only a weak inhibition of LPS-induced cytokine
release was observed with pEM-2 (D) in these in vitro experi-
ments. At the highest dose tested (100 g/ml), pEM-2 (D) re-
duced the level of TNF- secretion triggered by LPS by 25%,
whereas virtually no inhibition was recorded for pEM-2 (L)
(Fig. 5).
Effects of pEM-2 enantiomers on LPS-induced lethality and
serum TNF- levels. Injection of 10 g of E. coli LPS by the
i.p. route caused 100% lethality in galactosamine-sensitized
CD-1 mice within the first 24 h. As shown in Table 2, no re-
duction in lethality was observed when the mice were chal-
lenged with the same dose of LPS if it was previously incubated
with pEM-2 (L). In these animals, the serum TNF- levels 1 h
after challenge were not statistically different from those in the
control group receiving LPS alone. On the other hand, pEM-2
(D) prevented the endotoxin-induced lethality by nearly 40% in
three independent experiments. Moreover, serum TNF- lev-
els in pEM-2 (D)-treated mice decreased by more than 40%
compared to those in the nontreated control group receiving
LPS alone (Table 2).
Effect of pEM-2 (D) on E. coli or S. enterica serovar Typhi-
murium-induced lethal peritonitis. Injection of 5  108 E. coli
cells into the peritoneal cavities of CD-1 mice resulted in 100%
lethality, and this always occurred within 24 h (Table 3). In
mice that were immediately treated with 100 g of pEM-2 (D)
by the i.p. route, 25% survival was recorded after 72 h of ob-
servation. However, this reduction in lethality was not statisti-
cally significant by Fisher’s extact test (P  0.05). Similar re-
sults were obtained in experiments in which peritonitis was
induced with S. enterica serovar Typhimurium, in which treat-
ment of the mice with pEM-2 (D) rescued one of five animals
from lethality (P  0.05). No signs of acute toxicity were
observed in the control mice that received the peptide alone
(Table 3).
DISCUSSION
The bactericidal activity of myotoxin II against gram-positive
and gram-negative bacteria has been reproduced by a short
segment (positions 115 to 129) near its C-terminal loop (29)
which has characteristics that functionally resemble those of
natural antimicrobial cationic peptides. The original sequence
from positions 115 to 129 was initially modified to enhance its
hydrophobicity and ability to interact with membranes by re-
placing its three tyrosine residues by tryptophan. This change
(p115-W3) increased the bactericidal potency against E. coli by
1 order of magnitude, but toxicity toward eukaryotic cells was
also drastically potentiated (23). Such an enhancement of the
bactericidal effect of p115-W3 was confirmed in the present
study with a broader range of bacteria, including both gram-
positive and gram-negative species, as well as Brucella spp.,
which are known to be highly resistant to cationic peptides (9,
26). Nevertheless, due to the high degree of toxicity of p115-
W3, a series of modifications were examined for their effects
on the bactericidal and cytolytic potencies of the peptides (32).
From such analyses, pEM-2, a modified synthetic peptide,
was selected for further characterization. The present re-
sults showed that pEM-2 displays lower cytolytic activity
than p115-W3 toward myoblasts, with a toxicity comparable to
that of lactoferricin B, a well-characterized cationic peptide
with a high degree of bactericidal action and a low-level cyto-
toxic effect (3, 40). Interestingly, pEM-2 showed lower toxicity
toward myoblasts than polymyxin B, a peptide restricted to
topical therapeutic use (17).
Despite its lower toxicity, pEM-2 conserved the microbicidal
characteristics of p115-W3, suggesting the importance of its
tryptophan residues in affecting prokaryotic membranes. In
agreement with this, it was previously observed that if the
FIG. 5. Inhibition of endotoxin-induced TNF- release in RAW
264.7 cells by L and D enantiomers of pEM-2. E. coli O111:H4 LPS
(100 ng/ml) was incubated at 37°C for 30 min alone or with the pep-
tides (100 g/ml) and was then added to the cell cultures, as described
in Materials and Methods. , statistically significant difference (P 

0.05) between LPS alone and pEM-2 (D).
TABLE 2. Effects of pEM-2 (L) or pEM-2 (D) on serum TNF-









pEM-2 (L) 0/6 
40
LPS control 10/10 10,412  5,286
LPS  pEM-2 (L) 10/10 9,515 3,643
pEM-2 (D) 0/6 
40
LPS control 10/10 12,276  5,438
LPS  pEM-2 (D) 6/10b 7,241  4,189c
a All deaths occurred within the first 24 h of observation.
b Statistically significant difference (P 
 0.01) from the results for the control
group receiving LPS alone, by Fisher’s exact test.
c Statistically significant difference (P 
 0.01) from the results for the control
group receiving LPS alone, by Student’s t test.
TABLE 3. Effect of pEM-2 (D) on the lethality induced by




total no. of mice)b
Saline control ........................................................................... 0/4
pEM-2 (D)  saline ................................................................ 0/8
E. coli  saline......................................................................... 12/12
E. coli  pEM-2 (D)................................................................ 9/12c
S. enterica serovar Typhimurium  saline............................ 5/5
S. enterica serovar Typhimurium  pEM-2 (D)................... 4/5c
a E. coli ATCC 25922 and S. enterica serovar Typhimurium ATCC 14028.
b All deaths occurred within the first 24 h.
c Nonsignificant (P  0.05) reduction, by Fisher’s exact test.
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N-terminal hydrophobic segment of p115-W3, which contains
the tryptophan cluster, is replaced by the same cationic se-
quence of its C-terminal half (KKALAKLKALAKK), the pep-
tide loses all bactericidal activity (32).
The microbicidal spectrum of pEM-2 appears to be broad
and includes several gram-positive and gram-negative bacteria.
Thus, the actions of pEM-2 are similar to those of other cat-
ionic peptides such as lactoferricin (25) and P-113, a derivative
of histatin 5, which have lengths comparable to that of pEM-2
(31).
Although many investigations on the in vitro actions of cat-
ionic peptides have been performed, there are still disadvan-
tages when they are evaluated in vivo with animal models.
Their absorption is extremely poor, thus limiting oral admin-
istration, and high local concentrations of these compounds
are difficult to achieve. Two additional limitations include their
relatively high levels of toxicity as well as their rapid degrada-
tion by natural proteases (16). The former disadvantage has
been approached by attempting to make modifications to their
amino acid sequences in order to improve their selectivities
toward prokaryotes (7). On the other hand, the introduction of
D-amino acids in their sequences circumvents the actions of
proteases, while it preserves their bactericidal properties (36).
As observed in this study, pEM-2 (D) retained the bactericidal
potency of pEM-2 (L) against S. aureus and S. enterica serovar
Typhimurium, suggesting that use of the D enantiomer would
be an interesting alternative for exploration of the possible
antiendotoxic properties of pEM-2 in vivo.
Septic shock is the most common and, unfortunately, the
most dangerous complication of bacterial infection. LPS, a
complex macromolecule from the outer membranes of gram-
negative bacteria, is central to the pathophysiology of sepsis,
and lipid A is particularly central to the pathophysiology of
sepsis (1, 4, 11, 14, 33). The LAL assay was used to assess the
endotoxin-neutralizing potentials of pEM-2 enantiomers. In
this test, lipid A triggers a coagulation event based on an
enzymatic cascade. Therefore, peptides interacting with lipid A
of LPS can inhibit the LAL reaction. The results showed that
both pEM-2 (L) and pEM-2 (D) interact with LPS in vitro and
inhibit its triggering of the LAL reaction. The inhibition ob-
served with the L enantiomer was very similar to that caused by
polymyxin B, suggesting an interesting antiendotoxin potential
of the pEM-2 sequence. Nevertheless, pEM-2 (L) was unable
to prevent the LPS-triggered TNF- release from murine mac-
rophages in vitro, whereas pEM-2 (D) presented a significant,
although partial, inhibition (	25%) in comparison to that of
control cultures stimulated with LPS alone. These results agree
with the observation that pEM-2 (L)- or pEM-2 (D)-treated
macrophage cultures showed similar levels of the transcription
factors NF-B and AP-1 compared to those in the control
cultures stimulated with LPS alone (unpublished data). Some
studies have described similar findings, i.e., a weak inhibition
of TNF- release in vitro, despite the stronger inhibition ob-
served in vivo (35).
The differences in the inhibition of TNF- release caused by
the enantiomers might be explained by the possible degrada-
tion of pEM-2 (L) in the macrophage cultures. Experiments
with mice confirmed the better performance of pEM-2 (D) in
comparison to that of pEM-2 (L). Whereas the former de-
creased the rate of LPS-induced mortality by 40% (concomi-
tantly with a significant reduction in the levels of TNF- in
serum), no significant differences in lethality or in TNF- con-
centrations were observed in pEM-2 (L)-treated mice. These
results suggest that pEM-2 (L) might be rapidly eliminated by
proteolysis or renal clearance, similar to other small cationic
L-peptides (2, 6, 35, 38), whereas the half-life of pEM-2 (D)
might be more prolonged in vivo.
In the present work, pEM-2 was preincubated with LPS
before i.p. injection in mice in order to assess its antiendotoxic
ability independently of pharmacokinetic considerations. Also,
the potential of pEM-2 (D) to counteract a lethal bacterial
peritonitis process was evaluated immediately after adminis-
tration of the bacteria. The modest protection from lethality
observed in both models, with preincubation and by indepen-
dent administration, encourages the performance of further
studies with delayed administration of peptides to evaluate
their actual performance in established cases of endotoxemia
or sepsis. It was recently shown that the results derived from
septic shock models based on LPS injection are very similar to
those derived from other experimental models, such as cecal
ligation and puncture, which better reflect the conditions ob-
served in patients with sepsis (12). This suggests that pEM-2
(D) could also be assessed in such models, for example. Further
preclinical investigations are needed to evaluate the potential
of these peptides for the treatment of bacterial infections.
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